RT is characterised by higher molecular complexity than CLL and commonly involve lesions of suppression regulators (deletion and/or mutation of TP53), cell cycle (loss of CDKN2A), and cell proliferation (NOTCH1 mutation, MYC activation) [11]. The gene discussed is MYC; the disease is B-cell chronic lymphocytic leukemia.